John Theurer Cancer Center at Hackensack University Medical Center Study Tracks Long-Term Survival With First-Line Nivolumab Plus Ipilimumab in Patients With Advanced Non-Small-Cell Lung Cancer

Pooled analysis deepens clinical benefit knowledge and assesses survival impact

A recent study in the Annals of Oncology provided greater understanding of the clinical benefit of first-line nivolumab plus ipilimumab (NIVO + IPI), which prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC), in a large pooled patient population. 

• Durable responses and long-term survival benefits were observed across histologies/PD-L1 expression levels.
• Patients who showed a 1L NIVO + IPI treatment response at 6 months experienced improved post-landmark survival benefit.
• Responders with higher tumor burden reduction from baseline derived long-term overall survival benefit.

In this study, researchers pooled analyses of four 1L NIVO + IPI studies supporting the regimen’s efficacy for advanced NSCLC treatment. They assessed overall survival, progression-free survival, objective response rate, duration of response and safety. Landmark analyses of overall survival by response status at 6 months and by tumor burden reduction in responders to NIVO + IPI also were assessed.

The outcomes observed in this large patient population further support this first-line treatment option for advanced NSCLC.

Learn more about innovations in cancer treatments at Hackensack University Medical Center.